Platelet Dysfunction in Type 2 Diabetes

  1. Aaron I. Vinik, MD, PHD1,
  2. Tomris Erbas, MD1,
  3. Tae Sun Park, MD1,
  4. Roger Nolan, PHD2 and
  5. Gary L. Pittenger, PHD1
  1. 1Department of Medicine and Pathology/Anatomy/Neurobiology, the Strelitz Diabetes Research Institutes, Eastern Virginia Medical School, Norfolk, Virginia
  2. 2Cato Research Ltd., Research Triangle Park, North Carolina

    Abstract

    Insulin resistance is a uniform finding in type 2 diabetes, as are abnormalities in the microvascular and macrovascular circulations. These complications are associated with dysfunction of platelets and the neurovascular unit. Platelets are essential for hemostasis, and knowledge of their function is basic to understanding the pathophysiology of vascular disease in diabetes. Intact healthy vascular endothelium is central to the normal functioning of smooth muscle contractility as well as its normal interaction with platelets. What is not clear is the role of hyperglycemia in the functional and organic microvascular deficiencies and platelet hyperactivity in individuals with diabetes. The entire coagulation cascade is dysfunctional in diabetes. Increased levels of fibrinogen and plasminogen activator inhibitor 1 favor both thrombosis and defective dissolution of clots once formed. Platelets in type 2 diabetic individuals adhere to vascular endothelium and aggregate more readily than those in healthy people. Loss of sensitivity to the normal restraints exercised by prostacyclin (PGI2) and nitric oxide (NO) generated by the vascular endothelium presents as the major defect in platelet function. Insulin is a natural antagonist of platelet hyperactivity. It sensitizes the platelet to PGI2 and enhances endothelial generation of PGI2 and NO. Thus, the defects in insulin action in diabetes create a milieu of disordered platelet activity conducive to macrovascular and microvascular events.

    Footnotes

    • Address correspondence and reprint requests to Adrienne E. Nagy, Managing Editor, SCP Communications, Inc., 134 W. 29th St., 4th Fl., New York, NY 10001. E-mail: vinikai{at}evms.edu.

      Received for publication 8 August 2000 and accepted in revised form 20 April 2001.

      A.I.V. has acted as a consultant and/or served on the Speaker’s Bureau for the following companies: Pfizer, Parke-Davis, Amgen, Asta Medica, Merck, Athena, Pharmacia & UpJohn, SmithKline Beecham, Boston Medical Technologies, Global Medical Products, Sandoz Pharmaceuticals, Genetech, Alteon, Myelos Corporation, Eli Lilly, Bristol-Myers Squibb, Knoll Pharmaceuticals, Wyeth-Ayerst Laboratories, and Neurometrix. He has also received grant support from multiple organizations.

      A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

    « Previous | Next Article »Table of Contents